Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson’s disease

Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson’s disease

Elevated urine bis(monoacylglycerol)phosphate (BMP) levels have been found in gain-of-kinase function LRRK2 G2019S mutation carriers. Here, we have expanded urine BMP analysis to other Parkinson’s disease (PD) associated mutations and found them to be consistently elevated in carriers of LRRK2 G2019...

Full description

Saved in:
Bibliographic Details
Published in:NPJ Parkinson's Disease Vol. 9; no. 1; p. 52
Main Authors: Gomes, Sara, Garrido, Alicia, Tonelli, Francesca, Obiang, Donina, Tolosa, Eduardo, Martí, Maria José, Ruiz-Martínez, Javier, Vinagre-Aragón, Ana, Hernandez-Eguiazu, Haizea, Croitoru, Ioana, Marshall, Vicky L., Koenig, Theresa, Hotzy, Christoph, Hsieh, Frank, Sakalosh, Marianna, Tengstrand, Elizabeth, Padmanabhan, Shalini, Merchant, Kalpana, Bruecke, Christof, Pirker, Walter, Zimprich, Alexander, Sammler, Esther
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 04-04-2023
Nature Publishing Group
Nature Portfolio
Subjects:
692/308/575
692/617/375/1718
692/617/375/346/1718
Biomarkers
Biomedical and Life Sciences
Biomedicine
Brief Communication
Clinical trials
Hospitals
Kinases
Movement disorders
Mutation
Neurology
Neurosciences
Parkinson's disease
Phosphorylation
Polyamines
Urine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Elevated urine bis(monoacylglycerol)phosphate (BMP) levels have been found in gain-of-kinase function LRRK2 G2019S mutation carriers. Here, we have expanded urine BMP analysis to other Parkinson’s disease (PD) associated mutations and found them to be consistently elevated in carriers of LRRK2 G2019S and R1441G/C as well as VPS35 D620N mutations. Urine BMP levels are promising biomarkers for patient stratification and potentially target engagement in clinical trials of emerging targeted PD therapies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2373-8057
2373-8057
DOI:10.1038/s41531-023-00482-4